Kezar Life Sciences, Inc. is a biopharmaceutical company based in South San Francisco, CA, dedicated to developing innovative protein-targeting approaches for the treatment of chronic diseases. With a focus on regulating cellular function, Kezar is advancing novel, first-in-class small molecule therapies that selectively inhibit specific proteins involved in disease activation. By targeting multiple drivers of disease, their unique approaches have the potential to provide broad treatment effects across a range of chronic conditions.
Kezar's pipeline includes Zetomipzomib (KZR-616), a selective immunoproteasome inhibitor aimed at modulating the immune system to treat autoimmune diseases, and KZR-261, a protein secretion inhibitor designed to halt the proliferation of diseases in oncology and autoimmunity. Committed to improving patient outcomes, Kezar is actively seeking collaborative and innovative individuals to join their team in developing breakthrough treatments for autoimmune diseases and cancer.
Generated from the website